Boundless Bio Common Stock Performance
| BOLD Stock | USD 1.26 0.01 0.79% |
The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Boundless Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Boundless Bio is expected to be smaller as well. At this point, Boundless Bio Common has a negative expected return of -0.23%. Please make sure to confirm Boundless Bio's day median price, price action indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if Boundless Bio Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Boundless Bio Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | BODEGAS LAN UNVEILS BOLD REBRAND TO REFLECT A CONTEMPORARY VISION | 11/20/2025 |
2 | Acquisition by Patterson Matthew R of 4000 shares of Boundless Bio, at 2.19 subject to Rule 16b-3 | 12/16/2025 |
3 | Aquablu Makes U.S. Debut at CES 2026 with Aquablu BOLD, Launching Personalized Hydration at Scale | 01/06/2026 |
4 | 21Shares Lists Bitcoin-and-Gold BOLD ETP on London Stock Exchange | 01/13/2026 |
5 | Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway | 01/20/2026 |
| Begin Period Cash Flow | 24.3 M | |
| Total Cashflows From Investing Activities | -26.1 M |
Boundless | Build AI portfolio with Boundless Stock |
Boundless Bio Relative Risk vs. Return Landscape
If you would invest 149.00 in Boundless Bio Common on October 26, 2025 and sell it today you would lose (23.00) from holding Boundless Bio Common or give up 15.44% of portfolio value over 90 days. Boundless Bio Common is currently does not generate positive expected returns and assumes 2.9545% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Boundless, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Boundless Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Boundless Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Boundless Bio Common, and traders can use it to determine the average amount a Boundless Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Boundless Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Boundless Bio by adding Boundless Bio to a well-diversified portfolio.
Boundless Bio Fundamentals Growth
Boundless Stock prices reflect investors' perceptions of the future prospects and financial health of Boundless Bio, and Boundless Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Boundless Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (39.61 M) | ||||
| Shares Outstanding | 22.39 M | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.26 X | ||||
| EBITDA | (64.28 M) | ||||
| Net Income | (65.36 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 47.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (60.84 M) | ||||
| Earnings Per Share | (2.66) X | ||||
| Market Capitalization | 28.21 M | ||||
| Total Asset | 206.41 M | ||||
| Retained Earnings | (201.47 M) | ||||
| Working Capital | 146.25 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
About Boundless Bio Performance
By analyzing Boundless Bio's fundamental ratios, stakeholders can gain valuable insights into Boundless Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Boundless Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Boundless Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Boundless Bio Common performance evaluation
Checking the ongoing alerts about Boundless Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Boundless Bio Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Boundless Bio Common generated a negative expected return over the last 90 days | |
| Boundless Bio Common may become a speculative penny stock | |
| Boundless Bio Common has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (65.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway |
- Analyzing Boundless Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Boundless Bio's stock is overvalued or undervalued compared to its peers.
- Examining Boundless Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Boundless Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Boundless Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Boundless Bio's stock. These opinions can provide insight into Boundless Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Boundless Stock analysis
When running Boundless Bio's price analysis, check to measure Boundless Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio is operating at the current time. Most of Boundless Bio's value examination focuses on studying past and present price action to predict the probability of Boundless Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio's price. Additionally, you may evaluate how the addition of Boundless Bio to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |